Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) |
UH2, UH3 |
Clinical Trial Not Allowed |
10/11/2023 |
Lynn Sorbara, Ph.D. |
Assay Validation of High Quality Markers for Clinical Studies in Cancer |
PAR-20-314 (UH3 Clinical Trials Not Allowed) |
UH3 |
|
10/11/2023 |
Lynn Sorbara, Ph.D. |
Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health |
RFA-CA-24-005 (U01 Clinical Trial Optional) |
U01 |
Clinical Trial Optional |
10/14/2023 |
Vikrant Sahasrabuddhe, M.B.B.S., M.P.H., Dr.P.H. |
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers |
NOT-CA-21-028 |
|
|
01/08/2024 |
Natalie Abrams, Ph.D. |
Pancreatic Cancer Detection Consortium: Research Units |
PAR-21-334 (U01 Clinical Trial Optional) |
U01 |
Clinical Trial Optional |
06/12/2024 |
|
Notice of Intent to Publish a Funding Opportunity Announcement for Pre-Cancer Atlas (PCA) Research Centers |
NOT-CA-23-085 (U01 Clinical Trial Not Allowed) |
U01 |
Clinical Trial Not Allowed |
09/01/2024 |
Indu Kohaar, Ph.D. |
Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) |
NOT-OD-22-202 |
|
Clinical Trial Not Allowed |
04/16/2025 |
Nancy J. Emenaker, Ph.D., R.D.N., L.D., F.A.N.D. |
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research |
PAR-22-099 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
05/08/2025 |
Richard Mazurchuk, Ph.D. |
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers |
NOT-CA-23-004 |
|
|
07/02/2025 |
Matthew Young, Ph.D. |
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes |
PAR-22-131 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
09/08/2025 |
Richard Mazurchuk, Ph.D. |